Literature DB >> 15240486

Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea.

William Braunlin1, Qiuwei Xu, Patrick Hook, Richard Fitzpatrick, Jeffrey D Klinger, Robert Burrier, Caroline B Kurtz.   

Abstract

Tolevamer, (GT160-246), is a sodium salt of styrene sulfonate polymer that is under development for the treatment of diarrhea caused by infection with Clostridium difficile. Pulsed ultrafiltration binding experiments in phosphate buffer containing 0.15 M Na(+) provide per polymer chain dissociation constants of 133 nM and 8.7 microM for the binding of tolevamer to C. difficile toxins A and B, respectively. At 0.05 M Na(+), the binding of toxin A to tolevamer is irreversible, whereas the dissociation constant to toxin B under these conditions is 120 nM. Binding constants obtained from fluorescence polarization data for toxin A binding to tolevamer at 0.15 M Na(+) agree substantially with those obtained by pulsed ultrafiltration. The binding activity of tolevamer reported here correlates well with previously reported results for the inhibition of the biological activity of C. difficile toxins A and B. From the fluorescence polarization data, it is estimated that one toxin A molecule interacts with between 600 to 1000 monomer units on tolevamer at 0.15 M Na(+). Thus, the data suggest a very large interaction surface between polymer and toxin A.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240486      PMCID: PMC1304374          DOI: 10.1529/biophysj.104.041277

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  17 in total

Review 1.  Methods of screening combinatorial libraries using immobilized or restrained receptors.

Authors:  C P Woodbury; D L Venton
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-04-02

Review 2.  Ion distributions around DNA and other cylindrical polyions: theoretical descriptions and physical implications.

Authors:  C F Anderson; M T Record
Journal:  Annu Rev Biophys Biophys Chem       Date:  1990

3.  Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile.

Authors:  A P Limaye; D K Turgeon; B T Cookson; T R Fritsche
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

4.  Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients.

Authors:  L V McFarland; G W Elmer; W E Stamm; M E Mulligan
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

5.  Isoparametric analysis of binding and partitioning processes.

Authors:  R C Chatelier; W H Sawyer
Journal:  J Biochem Biophys Methods       Date:  1987-10

Review 6.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

7.  Treatment of recurrent antibiotic-associated pseudomembranous colitis.

Authors:  F J Tedesco
Journal:  Am J Gastroenterol       Date:  1982-04       Impact factor: 10.864

8.  Treatment and prevention of antimicrobial agent-induced colitis and diarrhae.

Authors:  W L George; R D Rolfe; S M Finegold
Journal:  Gastroenterology       Date:  1980-08       Impact factor: 22.682

9.  Pseudomembranous colitis. Association with antibiotics and therapy with cholestyramine.

Authors:  E J Burbige; F D Milligan
Journal:  JAMA       Date:  1975-03-17       Impact factor: 56.272

10.  Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins.

Authors:  N S Taylor; J G Bartlett
Journal:  J Infect Dis       Date:  1980-01       Impact factor: 5.226

View more
  12 in total

1.  Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A.

Authors:  Jason G S Ho; Antonio Greco; Maja Rupnik; Kenneth K-S Ng
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

2.  Treatment of Recurrent Clostridium difficile Diarrhea.

Authors:  Elizabeth S Huebner; Christina M Surawicz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-03

3.  A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.

Authors:  Jennifer Peppe; Andrew Porzio; David M Davidson
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

4.  Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection.

Authors:  Simon D Baines; Jane Freeman; Mark H Wilcox
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

Review 5.  Polymeric drugs: Advances in the development of pharmacologically active polymers.

Authors:  Jing Li; Fei Yu; Yi Chen; David Oupický
Journal:  J Control Release       Date:  2015-09-26       Impact factor: 9.776

6.  Dexamethasone-pDMAEMA polymeric conjugates reduce inflammatory biomarkers in human intestinal epithelial monolayers.

Authors:  Simon Keely; Sinéad M Ryan; David M Haddleton; Adam Limer; Giuseppe Mantovani; Evelyn P Murphy; Sean P Colgan; David J Brayden
Journal:  J Control Release       Date:  2008-12-06       Impact factor: 9.776

7.  A tertiary amino-containing polymethacrylate polymer protects mucus-covered intestinal epithelial monolayers against pathogenic challenge.

Authors:  Simon Keely; Lee-Anne B Rawlinson; David M Haddleton; David J Brayden
Journal:  Pharm Res       Date:  2007-11-29       Impact factor: 4.200

8.  Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile.

Authors:  Paul L Hinkson; Carol Dinardo; Daniel DeCiero; Jeffrey D Klinger; Robert H Barker
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

9.  New advances in the treatment of Clostridium difficile infection (CDI).

Authors:  Dennis D Hedge; Joe D Strain; Jodi R Heins; Debra K Farver
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

10.  Clostridioides difficile Toxin A Remodels Membranes and Mediates DNA Entry Into Cells to Activate Toll-Like Receptor 9 Signaling.

Authors:  Xinhua Chen; Xiaotong Yang; Jaime de Anda; Jun Huang; Dan Li; Hua Xu; Kelsey S Shields; Mária Džunková; Joshua Hansen; Ishan J Patel; Eric U Yee; Douglas T Golenbock; Marianne A Grant; Gerard C L Wong; Ciarán P Kelly
Journal:  Gastroenterology       Date:  2020-08-22       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.